Stay Updated
For all press requests, please reach out to [email protected].
News and Reports
Epoch Times: Lower Prices for 10 Medicare Drugs Now in Effect: What to Know
Merith Basey, CEO for Patients For Affordable Drugs, said the negotiation brought overdue accountability to pharmaceutical manufacturers who have long charged higher prices to U.S. customers than to those in other countries. “This is a historic step, but it cannot be the last,” Basey said in a Jan. 1 statement. “Medicare negotiation must be protected, […]
News and Reports
Bloomberg Law: Trump, Biden Drug Price Control Efforts Set to Collide in 2026
Still, advocacy groups like Patients for Affordable Drugs have been supporting the program, viewing it as the “heart of what is really lowering drug prices,” according to its CEO, Merith Basey.
News and Reports
Bloomberg: Cancer’s Soaring Cost Wrecks Patients’ Finances in a Broken System
As part of the Inflation Reduction Act in 2022, Congress capped patient out-of-pocket costs at $2,000 in the Medicare prescription drug program. Trapp, who’s now a patient advocate for a non-profit group called Patients for Affordable Drugs, said that helped limit her own expenses once she qualified for Medicare through disability. But the cap only applies […]
Press Releases
Medicare’s First Negotiated Drug Prices Take Effect: a Win for Patients
Patients on Medicare begin seeing an average list price reduction of 63% percent on the first 10 blockbuster drugs starting January 1st WASHINGTON, D.C. — Today marks a historic milestone for prescription drug affordability in the United States. For the first time in Medicare’s history, lower negotiated prices for 10 of the most expensive and widely used prescription […]
News and Reports
IP Watchdog: Current and Former Lawmakers Lock Horns in Comments on USPTO’s Proposed PTAB Changes
Patients For Affordable Drugs (P4AD)“strongly oppose[s]” the proposed rule because, according to their submission, the PTAB “allows for more efficient, accessible, and affordable challenges to invalid patents,” particularly in the context of pharmaceutical patents. Prior to the American Invents Act (AIA), said P4AD, invalidating pharma patents “cost millions of dollars in district courts, harmed many communities, […]
News and Reports
Inside Health Policy: CMS Will Drop Three Part D Drugs From IRA Pricing Program In 2027
The upcoming removal of Entresto, Stelara and Xarelto from the negotiation program appears to be consistent with the inflation Reduction Act’s procedure for dropping drugs once competition enters the market. “The Medicare Negotiation Program was designed to serve as a check on the monopoly power of the pharmaceutical industry and the highest-cost and most commonly […]
News and Reports
Inside Health Policy: Trump’s CMS Secures Steeper MFPs For Second Round Of Negotiated Drugs
“This second round of negotiations marks another major milestone, delivering continued savings for patients that are consistent with the first round, and reinforcing that the Medicare Negotiation Program works. The inclusion of high-cost drugs like GLP-1s and more medications negotiated this round also means that savings to Medicare and taxpayers increased. Medicare negotiation is hugely […]
News and Reports
KFF Health News: FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office
Judy Aiken, a retired Portland, Maine, nurse who has taken Enbrel since 2007 to treat psoriatic arthritis, would be interested in trying the copycat if it costs her less. After retiring in 2019 and going on Medicare, she has spent thousands each year on the drug. The Biden-era Inflation Reduction Act capped her out-of-pocket drug […]